ALK account plan
Long-term allergy treatment provider
At a glance
ALK-Abelló is a Danish allergy pharma company: immunotherapy tablets, injections and drops plus anaphylaxis products, DKK 6,312 million revenue in FY2025.
ALK-Abelló A/S, headquartered in Hørsholm, Denmark and listed on Nasdaq Copenhagen (ALK B), develops, produces and markets products to diagnose and treat allergies, allergic asthma and acute anaphylactic reactions. Its core is disease-modifying allergy immunotherapy (AIT) in tablet, injection (SCIT) and drop form, where it estimates a ~48% global market share, alongside the Jext® adrenaline autoinjector and the neffy® nasal adrenaline spray. In FY2025 revenue grew 15% in local currencies to DKK 6,312 million, EBIT rose 53% to DKK 1,654 million (26% margin) and net profit was DKK 1,197 million. ALK had 2,711 employees, 9 production sites in Europe and the USA, and serves 44 markets directly and through partners such as GenSci (China), Torii/Shionogi (Japan) and ARS Pharma. The Lundbeck Foundation is a major shareholder; 59.2% of the B shares are free float.
Business units
Tablets (SLIT tablets)
about 53% of FY2025 revenue (DKK 3,335 million)Sublingual allergy tablets for grass, house dust mite, tree pollen, ragweed and Japanese cedar (GRAZAX®, ACARIZAX®, ITULAZAX®, RAGWITEK®, CEDARCURE™). ALK's primary revenue source, up 17% in FY2025 and 35% in Q3 2026 (DKK 999 million, 57% of quarterly revenue), helped by paediatric approvals: the HDM tablet is approved for children in 36 countries and launched in 24.
SCIT/SLIT drops
about 34% of FY2025 revenue (DKK 2,145 million)Injection-based immunotherapy (e.g. Alutard®), SLIT drops sold mainly in France, and SCIT bulk allergen extracts sold primarily to US allergists. Grew 5% in FY2025 but fell 6% in Q3 2026 to DKK 527 million on lower SCIT shipments to China, where sales and marketing passed to GenSci.
Anaphylaxis & other products
about 13% of FY2025 revenue (DKK 832 million)The Jext® adrenaline autoinjector, the neffy®/EURneffy® nasal adrenaline spray licensed from ARS Pharma, a next-generation autoinjector in development, plus diagnostics, PRE-PEN® and life-science products. Up 34% in FY2025; neffy® 2 mg is now launched in 14 markets.
Europe
71% of FY2025 revenue (DKK 4,459 million)ALK's core region with 2,161 employees; Germany alone is 25% of group revenue and France 16%. Revenue grew 14% in FY2025 and 18% in Q3 2026, led by tablets in Germany, Central and Eastern Europe and the UK. Led since 1 October 2025 by Flora Beiche-Scholz, EVP Commercial Operations Europe.
North America
16% of FY2025 revenue (DKK 1,037 million)533 employees, with manufacturing in Port Washington (NY), source materials in Post Falls (Idaho) and a main office in Round Rock (Texas). Revenue grew 19% in FY2025 and 8% in Q3 2026, with tablets mostly in Canada and neffy® co-promoted to US paediatricians. Led by Edward Jordan, EVP Commercial Operations North America from 5 January 2026.
International markets
13% of FY2025 revenue (DKK 816 million)Mostly partner-served: Japan (Torii, owned by Shionogi), China (GenSci), India (Dr. Reddy's) and Southeast Asia. Revenue grew 16% in FY2025; in Q3 2026 tablet revenue rose 47% on Japan shipments and royalties while SCIT drops fell against high China shipments a year earlier.
Strategic priorities
- Allergy+ strategy to 2028
- Help 5 million people with allergy a year by 2030 (3.1 million treated in 2025), with average organic revenue growth of at least 10% over 2023-2028, an EBIT margin around 25% and NIBD/EBITDA of at most two.
- Paediatric tablet expansion
- Roll out the house dust mite and tree tablets to children and reach paediatricians and ENT specialists as new prescriber groups; more than 4,000 prescribers in directly served markets had prescribed one of the two to children by end-2025.
- Make neffy® a success
- Launch EURneffy® in up to 15 European markets in 2026 and co-promote neffy® in the USA to ~9,000 paediatricians with a dedicated 65-rep sales force shared with ARS Pharma.
- Grow North America
- Grow North America by more than 10% a year towards 2028 by working beyond allergists, educating prescribers and payers, and preparing the peanut tablet launch.
- Food allergy pipeline
- Advance the peanut SLIT tablet (FDA Fast Track; phase 3 clinical trial application submitted), a tree nut tablet and the ALK014 biologic, which is progressing toward clinical development in 2027.
- Tablet capacity and digitalisation
- Upscale tablet production capacity to 800 million units a year by 2030 within the existing footprint, and invest in digitalisation and AI among the 2026 priorities.
Latest results
In Q3 2026 revenue rose 15% in local currencies to DKK 1,764 million (1,530) and EBIT rose 9% to DKK 469 million, a 27% margin (28%). Tablets grew 35% while SCIT/SLIT drops fell 6% on lower China shipments. Over the first nine months of 2026 revenue was DKK 5,330 million (+17%), EBIT DKK 1,484 million (+16%, 28% margin), net profit DKK 1,138 million and free cash flow DKK 1,192 million (836). Capacity costs rose 20%, with R&D up 24% and sales and marketing up 20% on paediatric tablet and neffy® launches. The full-year 2026 outlook, upgraded on 7 October, was confirmed: revenue growth of 16-17% in local currencies, an EBIT margin around 27% and free cash flow slightly above DKK 1,100 million.
Investments and deals
- Catalent tablet supply agreement
- Expanded in 2026: long-term access to the Zydis® formulation and tablet capacity of 1.1 billion a year from the early 2030s, for around half a billion DKK over 3 years.
- GenSci partnership in China
- DKK 244 million upfront, with ~DKK 300 million regulatory and up to ~DKK 780 million commercial milestones until 2039; the ACARIZAX® phase 3 bridging trial met its primary objective, with filing expected in H1 2027 and a possible launch late 2028.
- ARS Pharma neffy® licence
- About USD 145 million upfront for neffy® rights in most markets outside the US, plus US co-promotion in paediatrics; a DKK 32 million milestone was paid in 2025.
- 2026 capex
- Capex around DKK 400 million plus up to DKK 100 million under the Catalent agreement; ALK says its financial position lets it look increasingly at in-licensing and acquisitions.
- Partnerships for new markets and research
- Zuellig Pharma will sub-license neffy® in six Southeast Asian markets; a seed partnership with Allegria Therapeutics gives rights to negotiate in-licensing of up to three targets.
Challenges and risks
- Pricing and reimbursement pressure
- Market acceptance and authority-mandated price pressure are flagged as increasing risks; ALK is executing an action plan against Germany's mandatory rebate increase from 1 January 2027, and Germany is 25% of revenue.
- Structure of the US allergy market
- The US market grew around allergists compounding their own extracts, which the CEO says keeps North America closer to one fifth of revenue; the annual report cites allergists with a financial incentive to protect their legacy business.
- Product development risk
- Failures or delays in product development are flagged as an increasing risk; the peanut tablet phase 3 awaits FDA feedback on the clinical trial application.
- Supply and third-party dependence
- Production and quality issues and dependence on key third parties, notably for tablets, are among the main enterprise risks; SCIT initiations in Germany and the Nordics were limited by allergy-clinic capacity.
- Rising capacity costs
- Capacity costs rose 20% over the first nine months of 2026, and gross margin is expected to come under slight pressure as partner-related sales grow.
What leadership says
“ALK's 35% tablet growth in Q3 reflects the strength of our strategy, and paediatric use is increasingly contributing to the growth.”
“The constraint has not been demand, but the way the system itself evolved.”
“The objective is not to replace existing approaches, but to complement them and expand overall treatment capacity.”
“ALK is not a turnaround case, we are an established, successful company”
Where a supplier can help
- Launch support for paediatric tablets and neffy®
- The paediatric tablet roll-out and EURneffy® launches in up to 15 European markets need prescriber targeting, medical education and field-force tools aimed at paediatricians and ENT specialists.
- US market access and payer work
- The North America growth target depends on navigating insurers, PBMs and state-level variation and on educating prescribers beyond allergists, where market access and commercial analytics partners can help.
- Tablet manufacturing scale-up
- The capacity target of 800 million units a year by 2030 and the Catalent expansion create needs in production equipment, quality systems and supply-chain planning.
- Cost control against rebates
- With capacity costs up 20% and Germany's rebate increase from 2027, suppliers offering efficiency in commercial operations, procurement or the digitalisation and AI priority have a clear entry point.
- Clinical development services
- The peanut tablet phase 3, largely in the US and Canada, and ALK014 moving to the clinic in 2027 point to needs for CRO, regulatory and trial-recruitment support.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like ALK?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- ALK-Abelló Annual Report 2025 (Company release No 02/2026)
- ALK-Abelló (ALK) is a Danish pharmaceutical company focused on allergy: disease-modifying allergy immunotherapy (AIT) tablets, injections (SCIT) and drops, plus adrenaline autoinjectors (Jext®) and the nasal adrenaline spray neffy®; it estimates a ~48% global market share in AIT and holds less than 5% of the global anaphylaxis market.
- FY2025 revenue grew 15% in local currencies to DKK 6,312 million (5,537); EBIT rose 53% to DKK 1,654 million and the EBIT margin reached 26% (20%), delivering the "25-in-25" margin target set in 2021 when the margin was 4%.
- Tablets are the growth engine: DKK 3,335 million (+17%); SCIT/SLIT drops DKK 2,145 million (+5%); Anaphylaxis & other products DKK 832 million (+34%), driven by Jext® and neffy®.
- By region: Europe 71% of revenue (DKK 4,459 million, +14%), North America 16% (DKK 1,037 million, +19%), International markets 13% (DKK 816 million, +16%); Germany alone is 25% of revenue, France 16%, the USA 14%.
- Allergy+ strategy (to 2028): help 5 million people a year by 2030 (3.1 million treated in 2025, +500,000); financial ambitions of ≥10% average organic growth 2023-2028, ~25% EBIT margin and NIBD/EBITDA ≤2.
- 2025 milestones: paediatric launches of ACARIZAX® (21 markets) and ITULAZAX® (12 markets); EURneffy® reached close to 18% market share in Germany after 6 months; China partnership with GenSci (DKK 244 million upfront); US co-promotion of neffy® to ~9,000 paediatricians with 65 reps.
- Pipeline: phase 2 peanut SLIT tablet (FDA Fast Track; topline due Q2 2026), tree nut tablet and ALK014 biologic in pre-clinical, neffy® phase 2b in chronic spontaneous urticaria with ARS Pharma; tablet capacity target of 800 million units a year by 2030.
- 2026 outlook: revenue growth of 11-15% in local currencies, EBIT margin ~25%, capex around DKK 500 million, free cash flow DKK 800-1,000 million; dividends resumed at DKK 355 million (DKK 1.6 per share, ~30% of net profit).
- Key risks flagged as increasing: market acceptance and pricing/reimbursement pressure (incl. partner performance) and failures or delays in product development.
- Nine-month interim report (Q3) 2026 (Company release No 19/2026)
- Q3 2026 revenue rose 15% in local currencies to DKK 1,764 million (1,530); EBIT up 9% to DKK 469 million, margin 27% (28%).
- Tablets drove growth: DKK 999 million (+35%), 57% of Q3 revenue, with +33% in Europe, +32% in North America and +47% in International markets; paediatric use increasingly contributes.
- SCIT/SLIT drops fell 6% to DKK 527 million on lower SCIT shipments to China; Anaphylaxis & other products +1% to DKK 238 million.
- Nine months: revenue DKK 5,330 million (+17%), EBIT DKK 1,484 million (+16%, margin 28%), net profit DKK 1,138 million, free cash flow DKK 1,192 million (836); NIBD/EBITDA -0.7.
- Full-year 2026 outlook (upgraded 7 October) confirmed: revenue growth 16-17% in local currencies, EBIT margin ~27%, free cash flow slightly above DKK 1,100 million.
- China: phase 3 bridging trial of ACARIZAX® met its primary objective; filing with GenSci expected H1 2027, possible launch late 2028.
- Catalent partnership expanded: long-term access to Zydis® and tablet capacity of 1.1 billion a year from the early 2030s, for around half a billion DKK over 3 years.
- neffy® 2 mg launched in 14 markets (1 mg in 1); Zuellig Pharma to sub-license neffy® in six Southeast Asian markets; peanut tablet phase 3 awaiting FDA feedback on the clinical trial application.
- Capacity costs up 20% over nine months (R&D +24%, sales & marketing +20%); ALK is executing an action plan against Germany's mandatory rebate increase from 1 January 2027.
- Peter Halling - CEO & President, ALK (US market and Allergy+)
- CEO Peter Halling says North America accounts for closer to one fifth of ALK's revenues, far below the 30-50% typical of European specialty pharma, because the US allergy market grew around allergists compounding their own extracts.
- He sees the US as significantly underpenetrated: many patients never complete AIT or stay on symptomatic treatment; innovation (SLIT tablets incl. for children, nasal adrenaline, peanut programmes) is starting to open it.
- ALK's US footprint: manufacturing in Port Washington (NY), source materials in Post Falls (Idaho), sites in Oklahoma, Illinois and Washington, main office in Round Rock (Texas), operations in Bedminster (NJ); built over twenty years, ahead of onshoring debates.
- ARS Pharma deal was a licence and co-promotion, not an acquisition: about USD 145 million upfront for neffy® rights in most markets outside the US, with US co-promotion focused on paediatrics.
- Strategy reaches beyond allergists to paediatricians and ENT specialists; tablets approved for children as young as five allow earlier intervention.
- Edward Jordan (30+ years at Merck, Schering-Plough, Teva, DBV) named EVP and Head of Commercial Operations North America and brought into the executive team.
- Target: grow North America by more than 10% a year towards 2028, with room to outperform; peanut tablet phase 2 readout hoped for in H1 2026, possible launch around 2029-2030.
- Peter Halling - CEO and President, ALK (Allergy+ strategy and leadership)
- CEO Peter Halling presents ALK as a global leader in moderate-to-severe allergy, focused on disease-modifying allergy immunotherapy, with growing roles in food and venom allergy and anaphylaxis.
- ALK has ~3,000 employees and, after a period of negative EBIT, returned to sustained profitability, forecasting at the time a 25% EBIT margin and 9-13% top-line growth.
- Allergy+ strategy (announced at a Capital Markets Day in June of the previous year) has four pillars - Focus, Innovation, Optimisation, Cultivation - and aims to go from 2.5 million to over 5 million patients a year by 2030.
- Distinctive "field to pharmacy" model: ALK harvests allergen source materials itself, e.g. in Idaho and Washington.
- Europe is around 70% of the business, North America about 15% and Asia another 15%; investments are under way in the US, Canada, China and Japan.
- Partnerships: ARS Pharmaceuticals (intranasal epinephrine), Torii in Japan, AI research with McMaster University.
- He criticises European regulatory complexity and shortened IP protection, and asks Denmark to fix regulation, investment retention and talent mobility.
- Priorities for the next 3-5 years: rigorous execution of paediatric AIT approvals, anaphylaxis with ARS, and building a pipeline while staying profitable.
Questions about ALK
What does ALK do?
ALK-Abelló is a Danish pharmaceutical company focused on allergy. It sells disease-modifying allergy immunotherapy as tablets, injections and drops, and anaphylaxis products such as the Jext® autoinjector and the neffy® nasal adrenaline spray.
What is ALK's revenue?
FY2025 revenue was DKK 6,312 million, up 15% in local currencies, with EBIT of DKK 1,654 million. For 2026 ALK guides revenue growth of 16-17% in local currencies and an EBIT margin around 27%.
How many employees does ALK have?
ALK had 2,711 employees at end-2025: 2,161 in Europe, 533 in North America and 17 in International markets.
What is ALK's strategy?
Under Allergy+ ALK aims to help 5 million people a year by 2030, growing organically by at least 10% a year on average over 2023-2028 at an EBIT margin around 25%, driven by paediatric tablets, neffy® and a food allergy pipeline.
Who leads ALK?
Peter Halling is President & CEO, with Claus Steensen Sølje as EVP & CFO and Henriette Mersebach as EVP R&D. The board is chaired by Anders Hedegaard.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)